Core Viewpoint - Heng Rui Medicine (01276) has shown a strong performance with a more than 5% increase in stock price following the release of its mid-term results, indicating positive market sentiment towards the company's growth prospects [1] Financial Performance - The company reported a 16% year-on-year increase in revenue for the first half of the year, with product sales revenue growing approximately 13% after excluding collaboration income, driven primarily by rapid growth in innovative drug sales [1] - The stock price rose by 5.02%, reaching 76.3 HKD, with a trading volume of 387 million HKD [1] Share Buyback and Employee Stock Plan - Heng Rui Medicine plans to repurchase shares worth approximately 1 to 2 billion HKD for an employee stock ownership plan [1] - The conditions for full unlocking of this plan include achieving over 25% annual growth in innovative drug sales from 2025 to 2027, filing 5 to 8 new NDAs (including new indications) each year, and nearly 20 new molecular entity INDs [1] Innovation and Growth Strategy - Huayuan Securities highlighted the continuous growth in the company's innovative revenue and a positive trend in its transformation towards innovation [1] - The company has achieved multiple significant business development (BD) deals, with international expansion becoming an important second growth curve [1] - Heng Rui Medicine's well-structured and high-quality innovation pipeline presents numerous potential transaction opportunities, and as the company accelerates its internationalization process, the pipeline is expected to contribute to normalized profits, providing new growth points [1]